A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Titration of serum CEA, p53 antibodies and CEA-IgM complexes in patients with colorectal cancer
2009
Molecular Medicine Reports
The early detection of colorectal cancer is key to the improvement of patient survival. Although fecal occult blood testing and carcinoembryonic antigen (CEA) in serum are widely used as non-invasive screening methods, they have limited sensitivity. Forty-five patients who underwent surgery for primary colorectal cancer were enrolled in this study. Sixteen (36%) were determined to have Stage I tumors, 15 (33%) Stage II tumors and 14 (31%) Stage III tumors. Serum samples from a non-colorectal
doi:10.3892/mmr_00000124
pmid:21475853
fatcat:3rngjpeor5gpfe6kycyggs4psq